The Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK) is seeking a pediatric oncologist to join the Neuroblastoma Service as part of a team focused on the continued development of the science and treatment advances leading to optimal outcomes for this disease in children and young adults. We are actively seeking physicians that are BE/BC in pediatrics and pediatric hematology/oncology interested in an academic career.
Faculty from the Neuroblastoma Service serve as pediatric oncologists with a large portfolio of clinical trials encompassing all therapeutic categories: chemotherapy, radiopharmaceuticals, antibody-based immunotherapy, cell-based immunotherapy, anti-NB vaccines and personalized therapies directed by genomic findings. There is seamless interaction between translational and clinical research and clinical care and a well-established track record of innovation and developing unique therapies for neuroblastoma.
The faculty are pioneers in immunotherapy and have a large patient population with over 100 new patients per year. They are a large team with diverse talents and expertise with a team approach to clinical decision making. They have close interactions with other disciplines inside and outside the department and participate in multiple, varied areas of academic, scientific and educational initiatives.
This search is open to potential candidates at all levels of career experience and appointments will be made at an academic level commensurate with the appointee’s experience. As a member of the Neuroblastoma Service you will have the responsibility for:
Development and implementation of clinical trials for patients with neuroblastoma
Translational of preclinical data from Neuroblastoma Research Laboratory to the clinic
Incorporation of clinical trials into clinical care of patients with neuroblastoma
Direct patient care for patients with neuroblastoma
Supervising and managing immunotherapy: antibodies and cell-mediated immunotherapy
MIBG and other radiopharmaceuticals; radioimmunotherapy
High-dose chemotherapy and autologous stem cell transplants
1-2 days per week in outpatient practice
Academic activities including publications, education of fellows, residents and Advance Practice Providers
Participation in departmental activities, including provision of inpatient care on a rotational basis with all oncology faculty in the department.
Memorial Sloan Kettering Cancer Center’s Department of Pediatrics is the nation’s largest pediatric cancer program dedicated to the treatment of children, teenagers, and young adults with cancer, immune deficiencies and blood disorders, with more than 800 new patients each year. Comprising leading experts in the treatment of pediatric malignancies and immune deficiencies, over 70 faculty members within the Department of Pediatrics are dedicated to seeking novel approaches to achieve more-effective outcomes while reducing or minimizing the short-and long-term effects of treatment, both in the laboratory and in state-of-the-art clinical facilities.
Experience in design and implementation of clinical trials
Experience in translational research
The ability to work in a team environment including interaction with a large diverse team of care providers and data managers
Ability to innovate and think outside the box
Applicants must possess a full and unrestricted license to practice medicine in the State of New York (or must be licensed in another jurisdiction and be eligible for licensure in New York and New Jersey).
They must possess a Doctor of Medicine (MD), Osteopathy (DO) or equivalent.
Board-certified in Pediatrics; Board-certified or Board-eligible in Pediatric Hematology/Oncology.
Eligible for appointment at an academic rank ranging from Instructor to Assistant or Associate Professor.
Please direct CVs and confidential inquiries to:
Jennifer Weimer, Candidate Developer, MillicanSolutions, LLC.
Memorial Sloan Kettering Cancer Center — the world’s oldest and largest comprehensive cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 50 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.